+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

A

Actively Recruiting

Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.

Age: 18Years +All Genders
37 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.

Age: 18Years - 75YearsAll GendersPhase 3
201 locations
S

Actively Recruiting

Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.

Age: 18Years +All GendersPhase 3
42 locations
S

Actively Recruiting

Myeloproliferative Neoplasms MPN are blood cancers linked to a higher risk of blood clots. This research focuses on understanding how the presence of a genetic mutation called JAK2V617F in different blood cell types and endothelial cells relates to the risk of developing these clots. Researchers aim to identify specific patterns of this mutation in various cell populations that might help predict which patients are at higher risk for thrombosis. The study involves 120 patients diagnosed with either Polycythemia Vera PV or Essential Thrombocythemia ET. Blood samples will be collected to isolate platelets, red blood cells, granulocytes, and endothelial cells. Using digital PCR technology, the level of the JAK2V617F mutation will be measured in these cells. Patients with or without a history of thrombosis and different types of thrombosis will be compared to identify any associations with the mutation profiles. Participants will be involved at the time of diagnosis or within one year of diagnosis before starting cytoreductive treatment. Researchers will evaluate the mutation level in different blood cells and endothelial cells, assess the type of MPN, and measure the risk score for thrombosis. The main outcome is the history of thrombosis at diagnosis. This observational study does not involve treatment but collects blood samples and clinical data to better understand thrombosis risks in MPN patients.

Age: 18Years +All Genders
11 locations
C

Actively Recruiting

This research aims to evaluate a newly developed tool designed to assess the condition of the oral cavity in adult patients who are orally intubated in intensive care units. Oro-tracheal intubation often causes lesions in the mouth and throat, which can affect the patients hospital stay and quality of life. Currently, no assessment tools are specifically adapted for these intubated patients, highlighting the need for a specialized evaluation method. The study involves using the new Mouth Assessment Tool MAT by nurses to evaluate the oral condition of adults undergoing oro-tracheal intubation in intensive care. This tool has been created with input from experts in intensive care, oral health, hygiene, wound healing, and patient partners to ensure relevance and usability in daily nursing practice. The study will assess the tools metrological performance, content validity, construct validity, and reliability at the time of patient inclusion. Participants will be adults in intensive care who are orally intubated. Nurses will use the MAT to assess oral health at inclusion Day 0. Researchers will monitor how well the tool measures oral condition, its validity, and consistency. The study will evaluate the tools ability to support better mouth care protocols and improve patient outcomes by providing accurate assessments. The trial is observational and will continue until October 2028.

Age: 18Years +All Genders
10 locations
S

Actively Recruiting

Researchers are evaluating a combined physical therapy and yoga program with patient education to reduce osteoarticular and musculoskeletal pain caused by hormone therapy in women treated for breast cancer. This study addresses the common side effects of hormone therapy that affect quality of life and treatment adherence. The research also aims to examine changes in inflammatory markers to understand yogas potential impact on inflammation. Participants in the experimental group will attend one 90-minute yoga-therapeutic education session weekly for six weeks, led by a trained physical therapist. They will also practice daily 15-minute yoga sessions at home using guided audio tools for a total of 12 weeks. The control group will receive standard care without yoga sessions during the study but will be offered the program afterward. During the 12-week study, participants will undergo assessments of pain levels, compliance with the yoga program, physical flexibility, respiratory capacity, quality of life, fatigue, anxiety, depression, and self-competence. Researchers will track hormone therapy adherence and measure inflammatory biomarkers. These evaluations aim to determine if the combined intervention improves symptoms and overall well-being compared to standard care.

Age: 18Years - 99YearsFEMALEPhase Not Applicable
7 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the nutritional effects of a new hydrolyzed rice protein-based infant formula compared to a standard cows milk protein formula in healthy term infants. The study aims to determine if the daily weight gain of infants fed the experimental rice formula for the first four months is not worse than that of infants fed the standard formula. This trial is randomized and quadruple-masked, involving healthy singleton infants born at term with adequate birth weight. Participants are fed exclusively with either the experimental rice-based formula or the control cows milk formula starting from around 7 to 13 days old until they reach 120 days of age. Parents record any deviations from exclusive feeding, including intake of other foods or formulas. The study includes scheduled visits at postnatal days 20, 30, 60, 90, and 120 to monitor feeding, digestive tolerance, behavior, and formula acceptance. During the study, parents also assess their infants quality of life at enrollment and at days 60 and 120. Researchers measure daily weight gain as the primary outcome. The trial includes regular monitoring of feeding patterns and infant well-being through parent diaries and assessments over the four months. Participation lasts from enrollment until the infant reaches 120 days old, with ongoing data collection at specified intervals.

Age: 7Days - 13DaysAll GendersPhase Not Applicable
10 locations
C

Actively Recruiting

This research aims to evaluate the best way to manage fever in patients with septic shock who require mechanical ventilation and sedation. Septic shock is a severe condition with high mortality, often linked to infections like pneumonia. Fever can increase oxygen use and inflammation, potentially worsening organ failure, but may also slow bacterial and viral growth. Previous pilot studies showed that controlling fever with external cooling improved shock resolution and organ function, though effects on longer-term survival remain unclear. This trial compares two fever management strategies to see which better reduces mortality at 60 days. Participants will be randomly assigned to one of two groups one will receive fever control by external cooling to maintain normal body temperature for 48 hours, and the other will have their fever respected without antipyretic therapy. The study uses covariate-adaptive randomization and includes a subgroup with acute respiratory distress syndrome ARDS. An independent safety committee will monitor serious adverse events, and interim analyses may adjust enrollment based on results. Throughout the study, participants will be monitored for mortality at 60 days as the primary outcome. Secondary measures include organ function scores, days free from ventilators, kidney therapy, vasopressors, and monitoring for complications like shivering, seizures, hypothermia, arrhythmias, infections, ARDS development, and acute kidney injury. The trial spans several years, with detailed assessments during and after treatment to evaluate the impact of fever management strategies on patient outcomes.

Age: 18Years +All GendersPhase Not Applicable
33 locations
R

Actively Recruiting

This trial studies patients with oral cavity cancer who have undergone reconstructive surgery using a flap. The study aims to compare two approaches to post-operative radiotherapy one that spares the surgical flap and a standard approach that does not. The goal is to see if sparing the flap reduces treatment side effects while still controlling the cancer locally. Participants are randomly assigned to receive either standard post-operative radiotherapy without flap sparing or radiotherapy that spares the flap, using advanced techniques like IMRT with photons or proton therapy IMPT. Some patients may also receive chemotherapy or immunotherapy alongside radiotherapy. This study is a phase III trial designed to test the feasibility and outcomes of flap sparing during radiotherapy. During the study, participants will be monitored for cancer control two years after completing radiotherapy and for ear, nose, and throat toxicities within 12 months after treatment. Researchers will assess how well the cancer is controlled locally and measure treatment-related side effects. The study involves regular follow-up to track these outcomes over time, with participation lasting until the primary outcome assessment at two years post-radiotherapy and study completion in 2034.

Age: 18Years +All GendersPhase 3
30 locations
R

Actively Recruiting

Researchers are analyzing the real-world experience of patients treated with Glofitamab for relapsed or refractory large B-cell lymphoma DLBCL. This observational study focuses on patients who participated in the French Expanded Access Programme EAP, with more than 300 treated patients and a median follow-up expected to exceed nine months. The study particularly aims to confirm the response rates of Glofitamab in patients who have previously received CAR-T therapy and to determine the best timing to start the treatment. The study includes patients who received at least one infusion of Glofitamab following pretreatment with Obinutuzumab as part of the Early Phase Access program. The treatment details are collected retrospectively from patients enrolled before November 1, 2024. The primary outcome being assessed is the best complete response rate during treatment, based on investigator evaluation using Lugano 2014 criteria at six months. Participants data will be reviewed to measure treatment effectiveness and safety, including complete metabolic response rates, progression-free survival, event-free survival, overall survival, rates of immune-related side effects like neurotoxicity and cytokine release syndrome, ICU admissions, and hospitalization events over six months. This analysis helps to better understand Glofitamabs performance in a large real-world patient group, with continued monitoring of outcomes and adverse events during the follow-up period.

Age: 18Years +All Genders
30 locations

1-10 of 26

1